[{"Abstract":"There is no abstract associated with this presentation.","Actions":[{"Icon":null,"Label":"View Abstract","SubType":null,"Type":"ViewAbstract","Url":null},{"Icon":null,"Label":"View Video","SubType":null,"Type":"ViewPlayer","Url":null},{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Chairperson","AdditionalFields":[{"Key":"Topics","Value":",,"},{"Key":"Keywords","Value":",,,,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":[],"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":"<presenter><u><i>Michelle R. Arkin<\/i><\/u><\/presenter>. UCSF - University of California San Francisco, San Francisco, CA","CSlideId":"","ControlKey":"b3c108d4-c96b-42d1-93af-276766d22f51","ControlNumber":"11210","DisclosureBlock":"","End":"4\/8\/2024 10:16:00 AM","HasWebcast":null,"Highlights":[],"Id":"9834","IsPresentation":"False","IsSessionOrganizer":"False","Keywords":null,"MediaSource":"None","OtherContent":null,"PlayerUrl":null,"PlayerUrlReason":null,"PositionInSession":"1","PosterboardNumber":"","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"","PresenterBiography":null,"PresenterDisplayName":"Michelle Arkin, PhD","PresenterKey":"5d655f6e-93f9-44a9-9421-fd8cb31060be","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"Cochairperson","SearchResultFooter":"","SearchResultHeader":"Apr  8 2024 10:15AM","SessionId":"554","SessionOnDemand":"False","SessionTitle":"New Drugs on the Horizon: Part 3","ShowChatLink":"false","Start":"4\/8\/2024 10:15:00 AM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"Cochairperson","Topics":null,"cSlideId":""},{"Abstract":"There is no abstract associated with this presentation.","Actions":[{"Icon":null,"Label":"View Abstract","SubType":null,"Type":"ViewAbstract","Url":null},{"Icon":null,"Label":"View Video","SubType":null,"Type":"ViewPlayer","Url":null},{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Chairperson","AdditionalFields":[{"Key":"Topics","Value":",,"},{"Key":"Keywords","Value":",,,,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":[],"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":"<presenter><u><i>Ingo Hartung<\/i><\/u><\/presenter>. EMD Serono, Inc., Darmstadt, Germany","CSlideId":"","ControlKey":"21db8afe-2374-475e-9ff1-db82e19ab618","ControlNumber":"11218","DisclosureBlock":"","End":"4\/8\/2024 10:16:00 AM","HasWebcast":null,"Highlights":[],"Id":"9842","IsPresentation":"False","IsSessionOrganizer":"False","Keywords":null,"MediaSource":"None","OtherContent":null,"PlayerUrl":null,"PlayerUrlReason":null,"PositionInSession":"2","PosterboardNumber":"","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"","PresenterBiography":null,"PresenterDisplayName":"Ingo Hartung, PhD","PresenterKey":"e6bac6dc-9659-4c1c-a8ae-27f4729f96d8","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"Cochairperson","SearchResultFooter":"","SearchResultHeader":"Apr  8 2024 10:15AM","SessionId":"554","SessionOnDemand":"False","SessionTitle":"New Drugs on the Horizon: Part 3","ShowChatLink":"false","Start":"4\/8\/2024 10:15:00 AM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"Cochairperson","Topics":null,"cSlideId":""},{"Abstract":"There is no abstract associated with this presentation.","Actions":[{"Icon":null,"Label":"View Abstract","SubType":null,"Type":"ViewAbstract","Url":null},{"Icon":null,"Label":"View Video","SubType":null,"Type":"ViewPlayer","Url":null},{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Invited Speaker","AdditionalFields":[{"Key":"Topics","Value":",,"},{"Key":"Keywords","Value":",,,,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":[],"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":"<presenter><u><i>Michelle R. Arkin<\/i><\/u><\/presenter>. UCSF - University of California San Francisco, San Francisco, CA","CSlideId":"","ControlKey":"fcfd79e5-0fd6-4a66-bdfd-25f4c977cdc6","ControlNumber":"11336","DisclosureBlock":"","End":"4\/8\/2024 10:20:00 AM","HasWebcast":null,"Highlights":[],"Id":"9977","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":"None","OtherContent":null,"PlayerUrl":null,"PlayerUrlReason":null,"PositionInSession":"3","PosterboardNumber":"","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"","PresenterBiography":null,"PresenterDisplayName":"Michelle Arkin, PhD","PresenterKey":"5d655f6e-93f9-44a9-9421-fd8cb31060be","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"Introduction","SearchResultFooter":"","SearchResultHeader":"Apr  8 2024 10:15AM","SessionId":"554","SessionOnDemand":"False","SessionTitle":"New Drugs on the Horizon: Part 3","ShowChatLink":"false","Start":"4\/8\/2024 10:15:00 AM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"Introduction","Topics":null,"cSlideId":""},{"Abstract":"Abstract is embargoed at this time.","Actions":[{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Invited Speaker","AdditionalFields":[{"Key":"Topics","Value":"++CT02-01 Phase 0 clinical trials,,"},{"Key":"Keywords","Value":"Targeted alpha therapy,Prostate cancer,Pharmacokinetics,Imaging,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":null,"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":"<presenter><u><i>Sabine Zitzmann-Kolbe<\/i><\/u><\/presenter>, <presenter><i>Jacob Hesterman<\/i><\/presenter>, <presenter><i>Patricia E. Cole<\/i><\/presenter>, <presenter><i>Nicolas Salem<\/i><\/presenter>, <presenter><i>Alex Papple<\/i><\/presenter>, <presenter><i>Michael Jeffers<\/i><\/presenter>, <presenter><i>Goekben Koca<\/i><\/presenter>, <presenter><i>Thorsten Poethko<\/i><\/presenter>, <presenter><i>Miroslav Dostalek<\/i><\/presenter>, <presenter><i>Shawn Hillier<\/i><\/presenter>, <presenter><i>John W. Babich<\/i><\/presenter>. Bayer AG, Germany, Ratio Therapeutics, Boston, MA, Bayer US, Whippany, NJ, Bayer US, Cambridge, MA, Bayer AS, Oslo, Norway, Bayer AG, Wuppertal, Germany, Bayer AG, Basel, Switzerland","CSlideId":"","ControlKey":"399b8cc2-37b2-4850-bd6c-e05ab89a92ad","ControlNumber":"11211","DisclosureBlock":"","End":"4\/8\/2024 10:35:00 AM","HasWebcast":null,"Highlights":[],"Id":"9835","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":null,"OtherContent":null,"PlayerUrl":"https:\/\/files.abstractsonline.com\/SUPT\/101\/10517\/cfg-cattendee-cslide-player-view-content-embargoed.png","PlayerUrlReason":"Content is embargoed at this time.","PositionInSession":"4","PosterboardNumber":"","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"ND09","PresenterBiography":null,"PresenterDisplayName":"Sabine Zitzmann-Kolbe, PhD","PresenterKey":"d99618cb-cd77-436c-8282-e0e5bd1d1aa5","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"ND09. Actinium-225 -PSMA-Trillium (BAY 3563254): Preclinical evaluation and clinical imaging study of a novel 225Ac-labeled PSMA-targeting small molecule triad for the treatment of mCRPC","SearchResultFooter":"","SearchResultHeader":"Apr  8 2024 10:15AM","SessionId":"554","SessionOnDemand":"False","SessionTitle":"New Drugs on the Horizon: Part 3","ShowChatLink":"false","Start":"4\/8\/2024 10:20:00 AM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"Actinium-225 -PSMA-Trillium (BAY 3563254): Preclinical evaluation and clinical imaging study of a novel 225Ac-labeled PSMA-targeting small molecule triad for the treatment of mCRPC","Topics":null,"cSlideId":""},{"Abstract":"There is no abstract associated with this presentation.","Actions":[{"Icon":null,"Label":"View Abstract","SubType":null,"Type":"ViewAbstract","Url":null},{"Icon":null,"Label":"View Video","SubType":null,"Type":"ViewPlayer","Url":null},{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Other","AdditionalFields":[{"Key":"Topics","Value":",,"},{"Key":"Keywords","Value":",,,,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":[],"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":". ","CSlideId":"","ControlKey":"5a6d500d-e82f-4f08-9f54-4a02042dfc37","ControlNumber":"11236","DisclosureBlock":"","End":"4\/8\/2024 10:40:00 AM","HasWebcast":null,"Highlights":[],"Id":"9860","IsPresentation":"False","IsSessionOrganizer":"False","Keywords":null,"MediaSource":"None","OtherContent":null,"PlayerUrl":null,"PlayerUrlReason":null,"PositionInSession":"5","PosterboardNumber":"","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"","PresenterBiography":null,"PresenterDisplayName":null,"PresenterKey":null,"PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"Discussion","SearchResultFooter":"","SearchResultHeader":"Apr  8 2024 10:15AM","SessionId":"554","SessionOnDemand":"False","SessionTitle":"New Drugs on the Horizon: Part 3","ShowChatLink":"false","Start":"4\/8\/2024 10:35:00 AM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"Discussion","Topics":null,"cSlideId":""},{"Abstract":"Abstract is embargoed at this time.","Actions":[{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Invited Speaker","AdditionalFields":[{"Key":"Topics","Value":"++ET09-04 Molecular glues,,"},{"Key":"Keywords","Value":"Mitogen-activated protein kinase (MAPK) pathway,MEK inhibitor,RAF kinase,Small molecule inhibitor,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":null,"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":"<presenter><i>Meagan B. Ryan<\/i><\/presenter>, <presenter><i>Bradley Quade<\/i><\/presenter>, <presenter><i>Natasha Schenk<\/i><\/presenter>, <presenter><i>Zhong Fang<\/i><\/presenter>, <presenter><i>Marshall Zingg<\/i><\/presenter>, <presenter><i>Steven E. Cohen<\/i><\/presenter>, <presenter><i>Chun Li<\/i><\/presenter>, <presenter><i>Brooke M. Swalm<\/i><\/presenter>, <presenter><i>Aysegul Ozen<\/i><\/presenter>, <presenter><i>Chaoyang Ye<\/i><\/presenter>, <presenter><i>Maria Stella Ritorto<\/i><\/presenter>, <presenter><i>Xin Huang<\/i><\/presenter>, <presenter><i>Arvin C. Dar<\/i><\/presenter>, <presenter><i>Yongxin Han<\/i><\/presenter>, <presenter><i>Michael Hale<\/i><\/presenter>, <presenter><i>Margit Hagel<\/i><\/presenter>, <presenter><u><i>Klaus P. Hoeflich<\/i><\/u><\/presenter>. Nested Therapeutics, Inc., Cambridge, MA, Memorial Sloan Kettering Cancer Center, New York, NY","CSlideId":"","ControlKey":"30dee399-aa57-42ef-aad9-2dc6a87ea6b6","ControlNumber":"11212","DisclosureBlock":"","End":"4\/8\/2024 10:55:00 AM","HasWebcast":null,"Highlights":[],"Id":"9836","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":null,"OtherContent":null,"PlayerUrl":"https:\/\/files.abstractsonline.com\/SUPT\/101\/10517\/cfg-cattendee-cslide-player-view-content-embargoed.png","PlayerUrlReason":"Content is embargoed at this time.","PositionInSession":"6","PosterboardNumber":"","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"ND10","PresenterBiography":null,"PresenterDisplayName":"Klaus Hoeflich, PhD","PresenterKey":"fc17bf26-4db4-424a-84d4-b0d2a54f608e","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"ND10. NST-628 is a novel, potent, fully brain-penetrant MAPK pathway molecular glue that inhibits RAS- and RAF-driven cancers","SearchResultFooter":"","SearchResultHeader":"Apr  8 2024 10:15AM","SessionId":"554","SessionOnDemand":"False","SessionTitle":"New Drugs on the Horizon: Part 3","ShowChatLink":"false","Start":"4\/8\/2024 10:40:00 AM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"NST-628 is a novel, potent, fully brain-penetrant MAPK pathway molecular glue that inhibits RAS- and RAF-driven cancers","Topics":null,"cSlideId":""},{"Abstract":"There is no abstract associated with this presentation.","Actions":[{"Icon":null,"Label":"View Abstract","SubType":null,"Type":"ViewAbstract","Url":null},{"Icon":null,"Label":"View Video","SubType":null,"Type":"ViewPlayer","Url":null},{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Other","AdditionalFields":[{"Key":"Topics","Value":",,"},{"Key":"Keywords","Value":",,,,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":[],"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":". ","CSlideId":"","ControlKey":"82802014-3730-40f9-a532-55b46194902f","ControlNumber":"11237","DisclosureBlock":"","End":"4\/8\/2024 11:00:00 AM","HasWebcast":null,"Highlights":[],"Id":"9861","IsPresentation":"False","IsSessionOrganizer":"False","Keywords":null,"MediaSource":"None","OtherContent":null,"PlayerUrl":null,"PlayerUrlReason":null,"PositionInSession":"7","PosterboardNumber":"","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"","PresenterBiography":null,"PresenterDisplayName":null,"PresenterKey":null,"PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"Discussion","SearchResultFooter":"","SearchResultHeader":"Apr  8 2024 10:15AM","SessionId":"554","SessionOnDemand":"False","SessionTitle":"New Drugs on the Horizon: Part 3","ShowChatLink":"false","Start":"4\/8\/2024 10:55:00 AM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"Discussion","Topics":null,"cSlideId":""},{"Abstract":"Abstract is embargoed at this time.","Actions":[{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Invited Speaker","AdditionalFields":[{"Key":"Topics","Value":"++CT01-01 Phase I clinical trials in progress,,"},{"Key":"Keywords","Value":"Microsatellite instability,Synthetic lethality,Small molecule drugs,WRN helicase,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":null,"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":"<presenter><u><i>Shota Kikuchi<\/i><\/u><\/presenter>, <presenter><i>Piergiorgio Pettazzoni<\/i><\/presenter>, <presenter><i>Kristen A. Baltgalvis<\/i><\/presenter>, <presenter><i>Kelsey N. Lamb<\/i><\/presenter>, <presenter><i>Kent T. Symons<\/i><\/presenter>, <presenter><i>Chu-Chiao Wu<\/i><\/presenter>, <presenter><i>Melissa A. Hoffman<\/i><\/presenter>, <presenter><i>Aaron N. Snead<\/i><\/presenter>, <presenter><i>Xiaodan Song<\/i><\/presenter>, <presenter><i>Thomas Glaza<\/i><\/presenter>, <presenter><i>Jason C. Green<\/i><\/presenter>, <presenter><i>Donald C. Rogness<\/i><\/presenter>, <presenter><i>Betty Lam<\/i><\/presenter>, <presenter><i>Maria E. Rodriguez-Aguirre<\/i><\/presenter>, <presenter><i>David R. Woody<\/i><\/presenter>, <presenter><i>Christie L. Eissler<\/i><\/presenter>, <presenter><i>Socorro Rodiles<\/i><\/presenter>, <presenter><i>Seth M. Negron<\/i><\/presenter>, <presenter><i>Steffen M. Bernard<\/i><\/presenter>, <presenter><i>Eileen Tran<\/i><\/presenter>, <presenter><i>Jonathan Pollock<\/i><\/presenter>, <presenter><i>Ali Tabatabaei<\/i><\/presenter>, <presenter><i>Victor Contreras<\/i><\/presenter>, <presenter><i>Heather N. Williams<\/i><\/presenter>, <presenter><i>Martha K. Pastuszka<\/i><\/presenter>, <presenter><i>John J. Sigler<\/i><\/presenter>, <presenter><i>Markus G. Rudolph<\/i><\/presenter>, <presenter><i>Moritz Classen<\/i><\/presenter>, <presenter><i>Doris Brugger<\/i><\/presenter>, <presenter><i>Christopher Claiborne<\/i><\/presenter>, <presenter><i>Jean-Marc Plancher<\/i><\/presenter>, <presenter><i>Isabel Cuartas<\/i><\/presenter>, <presenter><i>Joan Seoane<\/i><\/presenter>, <presenter><i>Laurence E. Burgess<\/i><\/presenter>, <presenter><i>Robert T. Abraham<\/i><\/presenter>, <presenter><i>David S. Weinstein<\/i><\/presenter>, <presenter><i>Gabriel M. Simon<\/i><\/presenter>, <presenter><i>Matthew P. Patricelli<\/i><\/presenter>, <presenter><i>Todd M. Kinsella<\/i><\/presenter>. Vividion Therapeutics, San Diego, CA, Pharma Research and Early Development pRed F. Hoffman-La Roche, Ltd., Basel, Switzerland, Vall d'Hebron Institute of Oncology, Vall d'Hebron University Hospital, Universitat Aut√≤noma de Barcelona, CIBERONC, Barcelona, Spain","CSlideId":"","ControlKey":"0c62f613-cbc9-49fa-9136-4084fdaf794c","ControlNumber":"11214","DisclosureBlock":"","End":"4\/8\/2024 11:07:00 AM","HasWebcast":null,"Highlights":[],"Id":"9838","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":null,"OtherContent":null,"PlayerUrl":"https:\/\/files.abstractsonline.com\/SUPT\/101\/10517\/cfg-cattendee-cslide-player-view-content-embargoed.png","PlayerUrlReason":"Content is embargoed at this time.","PositionInSession":"8","PosterboardNumber":"","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"ND11","PresenterBiography":null,"PresenterDisplayName":"Shota Kikuchi, PhD","PresenterKey":"bbeeb622-b797-44eb-92a0-4054a1d7024d","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"ND11. Chemoproteomic-enabled discovery of VVD-214, a synthetic lethal allosteric inhibitor of WRN helicase","SearchResultFooter":"","SearchResultHeader":"Apr  8 2024 10:15AM","SessionId":"554","SessionOnDemand":"False","SessionTitle":"New Drugs on the Horizon: Part 3","ShowChatLink":"false","Start":"4\/8\/2024 11:00:00 AM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"Chemoproteomic-enabled discovery of VVD-214, a synthetic lethal allosteric inhibitor of WRN helicase","Topics":null,"cSlideId":""},{"Abstract":"Abstract is embargoed at this time.","Actions":[{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Invited Speaker","AdditionalFields":[{"Key":"Topics","Value":",,"},{"Key":"Keywords","Value":",,,,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":null,"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":"<presenter><u><i>Piergiorgio Pettazzoni<\/i><\/u><\/presenter>. Hoffman-La Roche, Ltd., Basel, Switzerland","CSlideId":"","ControlKey":"d0cba51c-2abf-4225-a8a0-eb5caaac3578","ControlNumber":"11215","DisclosureBlock":"","End":"4\/8\/2024 11:15:00 AM","HasWebcast":null,"Highlights":[],"Id":"9839","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":null,"OtherContent":null,"PlayerUrl":"https:\/\/files.abstractsonline.com\/SUPT\/101\/10517\/cfg-cattendee-cslide-player-view-content-embargoed.png","PlayerUrlReason":"Content is embargoed at this time.","PositionInSession":"9","PosterboardNumber":"","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"ND11","PresenterBiography":null,"PresenterDisplayName":"Piergiorgio Pettazzoni, PhD","PresenterKey":"e5139702-023b-4c80-bb80-fa74c6231eca","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"ND11. Chemoproteomic-enabled discovery of VVD-214, a synthetic lethal allosteric inhibitor of WRN helicase","SearchResultFooter":"","SearchResultHeader":"Apr  8 2024 10:15AM","SessionId":"554","SessionOnDemand":"False","SessionTitle":"New Drugs on the Horizon: Part 3","ShowChatLink":"false","Start":"4\/8\/2024 11:07:00 AM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"Chemoproteomic-enabled discovery of VVD-214, a synthetic lethal allosteric inhibitor of WRN helicase","Topics":null,"cSlideId":""},{"Abstract":"There is no abstract associated with this presentation.","Actions":[{"Icon":null,"Label":"View Abstract","SubType":null,"Type":"ViewAbstract","Url":null},{"Icon":null,"Label":"View Video","SubType":null,"Type":"ViewPlayer","Url":null},{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Other","AdditionalFields":[{"Key":"Topics","Value":",,"},{"Key":"Keywords","Value":",,,,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":[],"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":". ","CSlideId":"","ControlKey":"aed59404-9490-4be0-b7df-a4ea7dc749ed","ControlNumber":"11238","DisclosureBlock":"","End":"4\/8\/2024 11:20:00 AM","HasWebcast":null,"Highlights":[],"Id":"9862","IsPresentation":"False","IsSessionOrganizer":"False","Keywords":null,"MediaSource":"None","OtherContent":null,"PlayerUrl":null,"PlayerUrlReason":null,"PositionInSession":"10","PosterboardNumber":"","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"","PresenterBiography":null,"PresenterDisplayName":null,"PresenterKey":null,"PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"Discussion","SearchResultFooter":"","SearchResultHeader":"Apr  8 2024 10:15AM","SessionId":"554","SessionOnDemand":"False","SessionTitle":"New Drugs on the Horizon: Part 3","ShowChatLink":"false","Start":"4\/8\/2024 11:15:00 AM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"Discussion","Topics":null,"cSlideId":""},{"Abstract":"Abstract is embargoed at this time.","Actions":[{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Invited Speaker","AdditionalFields":[{"Key":"Topics","Value":"++ET09-05 Novel antitumor agents,,"},{"Key":"Keywords","Value":"CDK4,Breast cancer,CDK inhibitor,Prostate cancer,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":null,"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":"<presenter><u><i>Lars Anders<\/i><\/u><\/presenter>, <presenter><i>Gary Gallego<\/i><\/presenter>. Pfizer Oncology, San Diego, CA","CSlideId":"","ControlKey":"4ca0f545-6bcc-4aec-aaa6-d3273fc3b014","ControlNumber":"11216","DisclosureBlock":"","End":"4\/8\/2024 11:27:00 AM","HasWebcast":null,"Highlights":[],"Id":"9840","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":null,"OtherContent":null,"PlayerUrl":"https:\/\/files.abstractsonline.com\/SUPT\/101\/10517\/cfg-cattendee-cslide-player-view-content-embargoed.png","PlayerUrlReason":"Content is embargoed at this time.","PositionInSession":"11","PosterboardNumber":"","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"ND12","PresenterBiography":null,"PresenterDisplayName":"Lars Anders, PhD","PresenterKey":"6bce197b-bcf4-4364-ae38-2b175c6fe91e","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"ND12. Discovery of PF-07220060, a potent and selective CDK4 inhibitor","SearchResultFooter":"","SearchResultHeader":"Apr  8 2024 10:15AM","SessionId":"554","SessionOnDemand":"False","SessionTitle":"New Drugs on the Horizon: Part 3","ShowChatLink":"false","Start":"4\/8\/2024 11:20:00 AM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"Discovery of PF-07220060, a potent and selective CDK4 inhibitor","Topics":null,"cSlideId":""},{"Abstract":"Abstract is embargoed at this time.","Actions":[{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Invited Speaker","AdditionalFields":[{"Key":"Topics","Value":",,"},{"Key":"Keywords","Value":",,,,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":null,"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":"<presenter><u><i>Gary Gallego<\/i><\/u><\/presenter>. Pfizer, Inc., New York, NY","CSlideId":"","ControlKey":"4d361d38-52ea-4385-9291-9abb61700efc","ControlNumber":"11217","DisclosureBlock":"","End":"4\/8\/2024 11:35:00 AM","HasWebcast":null,"Highlights":[],"Id":"9841","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":null,"OtherContent":null,"PlayerUrl":"https:\/\/files.abstractsonline.com\/SUPT\/101\/10517\/cfg-cattendee-cslide-player-view-content-embargoed.png","PlayerUrlReason":"Content is embargoed at this time.","PositionInSession":"12","PosterboardNumber":"","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"ND12","PresenterBiography":null,"PresenterDisplayName":"Gary Gallego","PresenterKey":"7385abcd-ac7f-488c-8897-b50f325101c5","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"ND12. Discovery of PF-07220060, a potent and selective CDK4 inhibitor","SearchResultFooter":"","SearchResultHeader":"Apr  8 2024 10:15AM","SessionId":"554","SessionOnDemand":"False","SessionTitle":"New Drugs on the Horizon: Part 3","ShowChatLink":"false","Start":"4\/8\/2024 11:27:00 AM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"Discovery of PF-07220060, a potent and selective CDK4 inhibitor","Topics":null,"cSlideId":""},{"Abstract":"There is no abstract associated with this presentation.","Actions":[{"Icon":null,"Label":"View Abstract","SubType":null,"Type":"ViewAbstract","Url":null},{"Icon":null,"Label":"View Video","SubType":null,"Type":"ViewPlayer","Url":null},{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Other","AdditionalFields":[{"Key":"Topics","Value":",,"},{"Key":"Keywords","Value":",,,,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":[],"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":". ","CSlideId":"","ControlKey":"bc513d3e-bf24-4ed9-8c82-fb78ece25cf4","ControlNumber":"11239","DisclosureBlock":"","End":"4\/8\/2024 11:40:00 AM","HasWebcast":null,"Highlights":[],"Id":"9863","IsPresentation":"False","IsSessionOrganizer":"False","Keywords":null,"MediaSource":"None","OtherContent":null,"PlayerUrl":null,"PlayerUrlReason":null,"PositionInSession":"13","PosterboardNumber":"","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"","PresenterBiography":null,"PresenterDisplayName":null,"PresenterKey":null,"PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"Discussion","SearchResultFooter":"","SearchResultHeader":"Apr  8 2024 10:15AM","SessionId":"554","SessionOnDemand":"False","SessionTitle":"New Drugs on the Horizon: Part 3","ShowChatLink":"false","Start":"4\/8\/2024 11:35:00 AM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"Discussion","Topics":null,"cSlideId":""},{"Abstract":"There is no abstract associated with this presentation.","Actions":[{"Icon":null,"Label":"View Abstract","SubType":null,"Type":"ViewAbstract","Url":null},{"Icon":null,"Label":"View Video","SubType":null,"Type":"ViewPlayer","Url":null},{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Invited Speaker","AdditionalFields":[{"Key":"Topics","Value":",,"},{"Key":"Keywords","Value":",,,,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":[],"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":"<presenter><u><i>Ingo Hartung<\/i><\/u><\/presenter>. EMD Serono, Inc., Darmstadt, Germany","CSlideId":"","ControlKey":"376e071d-e8a2-4b09-adec-71dfcf52010d","ControlNumber":"11337","DisclosureBlock":"","End":"4\/8\/2024 11:45:00 AM","HasWebcast":null,"Highlights":[],"Id":"9978","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":"None","OtherContent":null,"PlayerUrl":null,"PlayerUrlReason":null,"PositionInSession":"14","PosterboardNumber":"","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"","PresenterBiography":null,"PresenterDisplayName":"Ingo Hartung, PhD","PresenterKey":"e6bac6dc-9659-4c1c-a8ae-27f4729f96d8","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"Closing remarks","SearchResultFooter":"","SearchResultHeader":"Apr  8 2024 10:15AM","SessionId":"554","SessionOnDemand":"False","SessionTitle":"New Drugs on the Horizon: Part 3","ShowChatLink":"false","Start":"4\/8\/2024 11:40:00 AM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"Closing remarks","Topics":null,"cSlideId":""}]